According to a new report Asia Pacific Antibiotics Market, published by KBV research, the Asia Pacific Antibiotics Market would witness market growth of 6.6% CAGR during the forecast period (2020-2026).
The China market dominated the Asia Pacific Antibiotics Market by Country in 2019, and would continue to be a dominant market till 2026. The India market is experiencing a CAGR of 6.9% during (2020 - 2026). Additionally, The Japan market is anticipated to witness a CAGR of 7% during (2020 - 2026).
The Cell Wall Synthesis Inhibitors market dominated the South Korea Antibiotics Market by Action Mechanism in 2019, growing at a CAGR of 5 % during the forecast period. The Protein Synthesis Inhibitors market is exhibiting a CAGR of 5.5% during (2020 - 2026). Additionally, The Mycolic Acid Inhibitors market is estimated to grow at the highest CAGR of 8.3% during (2020 - 2026).
The Cephalosporin market dominated the Malaysia Antibiotics Market by Drug Class in 2019, thereby, achieving a market value of $371 million by 2026. The Penicillin market would showcase a CAGR of 4.9% during (2020 - 2026). The Fluoroquinolone market is witnessing a CAGR of 7.8% during (2020 - 2026). Additionally, The Macrolides market is expected to witness highest CAGR of 7.8% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/asia-pacific-antibiotics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
By Action Mechanism
By Drug Class
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
